Cereno Scientific, a clinical stage biotech with an innovative portfolio in common and rare CVD, appoints Julia Fransson as Director of Business Development
Cereno Scientific (Nasdaq First North: CRNO B) today announced that Julia Fransson has joined the company as Director of Business Development. She joins the clinical stage biotech at an exciting point of the company’s growth journey, in developing innovative treatments for common and rare cardiovascular disease, with lead candidate drug CS1 in phase II in orphan disease PAH which is to deliver top line study results by Q2 this year.
“As our innovative portfolio of candidate drugs are progressing well, we need to scale our capacity on the business development side of our operations. Julia will be a great addition to our team and I am looking forward to see her developing value leverage to our BD strategies as well as working across functions to coordinate our commercial business focus,” said Sten R. Sörensen, CEO at Cereno Scientific.
Julia Fransson is an experienced business development professional in the life science industry. She is skilled in crafting strong and focused strategies, translating key scientific and market insights toward investors and partners as well as business modelling market analysis and biotech asset valuation. Previous roles include management positions within developing technology companies as well as, most recently, heading up a boutique life science strategy advisory firm. Julia holds a B.Sc. in Biotechnology and a M.Sc. in Business Design in life science companies from Chalmers University of Technology, Sweden.
For further information, please contact:
Henrik Westdahl, Director IR & Communications
Email: henrik.westdahl@cerenoscientific.com
Phone: +46 708 17 59 96
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q2 2024. Since January 2024, CS1 has been available under FDA’s Expanded Access Program (“compassionate use”) for continued CS1 treatment in patients who have completed the Phase II study. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.